Drug Profile


Alternative Names: FE-202158

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Peptides; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin 1a receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Septic shock

Most Recent Events

  • 22 Jun 2015 Phase-II/III clinical trials in Septic shock in Belgium (IV) (EudraCT2014-003973-41)
  • 22 Jun 2015 Phase II development is ongoing in USA, Canada, Belgium and Denmark
  • 11 May 2012 Ferring Pharmaceuticals plans a phase II trial for Septic shock in Belgium and Denmark (NCT01612676)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top